LeMaitre Vascular, Inc. $LMAT Shares Purchased by Pittenger & Anderson Inc.

Pittenger & Anderson Inc. lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 156.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 11,450 shares of the medical instruments supplier’s stock after purchasing an additional 6,990 shares during the quarter. Pittenger & Anderson Inc.’s holdings in LeMaitre Vascular were worth $929,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Cornerstone Planning Group LLC lifted its holdings in shares of LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the last quarter. MAI Capital Management acquired a new position in shares of LeMaitre Vascular in the 3rd quarter worth approximately $38,000. First Horizon Corp acquired a new position in shares of LeMaitre Vascular in the 3rd quarter worth approximately $39,000. Geneos Wealth Management Inc. lifted its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 2nd quarter worth approximately $47,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider directly owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This represents a 13.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 55,930 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer directly owned 1,476,500 shares in the company, valued at approximately $159,181,465. This represents a 3.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 215,438 shares of company stock valued at $23,062,911. Insiders own 9.50% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $112.04 on Monday. LeMaitre Vascular, Inc. has a fifty-two week low of $78.01 and a fifty-two week high of $118.01. The firm’s 50 day moving average price is $108.90 and its 200 day moving average price is $93.99. The company has a market cap of $2.56 billion, a P/E ratio of 44.64, a PEG ratio of 3.23 and a beta of 0.60. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. During the same period in the prior year, the firm earned $0.49 EPS. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were given a $0.25 dividend. The ex-dividend date of this dividend was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s payout ratio is currently 39.84%.

Analysts Set New Price Targets

LMAT has been the topic of several recent research reports. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Citizens Jmp upped their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Roth Mkm reaffirmed a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Finally, Wells Fargo & Company upped their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.